Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847674 · ClinicalTrials.gov registry record · Phase 2
A Study to Test if TEV-53275 is Effective in Relieving Asthma
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT04847674 is a Phase 2 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 97 participants.
The verdict
NCT04847674, a Phase 2 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo. A secondary objective is to evaluate the efficacy of TEV-53275 compared to placebo assessed by lung function, asthma symptoms, rescue medication use, and quality of life measures. Another secondary objective is to evaluate the safety and tolerability of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype compared with placebo, and lastly, to evaluate the immunogenicity of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype.
Interventions
- DRUG Placebo
- DRUG TEV-53275 Dose A
- DRUG TEV-53275 Dose B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04847674
The ClinicalTrials.gov registry entry for NCT04847674 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04847674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04847674 about?
NCT04847674 is a clinical study titled "A Study to Test if TEV-53275 is Effective in Relieving Asthma". The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo. A secondary objective is to evaluate the efficacy of TEV-53275 compared to placebo assessed by ...
What is the current status of trial NCT04847674?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2021-05-04. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT04847674?
The interventions under investigation include: Placebo (DRUG), TEV-53275 Dose A (DRUG), TEV-53275 Dose B (DRUG).
Who is sponsoring clinical trial NCT04847674?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.